The Board of Director in its meeting held today, August 12, 2026, approved the appointment of directors.

August 12, 2026 BSE Limited National Stock Exchange of India Ltd Department of Corporate Relationship Department of Corporate Services 1st Floor, New Trade Ring, Rotunda Building Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers C-1, Block G,Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (E), Mumbai – 400 051 Scrip Code: 524742 Scrip Code: CAPLIPOINT. Dear Sir/Madam, Sub: Appointment of Directors - Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, this is to inform you that the following changes in the composition of the Board of Directors of the Company have been effected at the meeting of the Board held on August 12, 2026, based on the recommendation of the Nomination and Remuneration Committee: 1. Approved the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company for a further period of two (2) years, with effect from August 25, 2026, to August 24, 2028, subject to the approval of the Shareholders at the ensuing AGM. 2. Approved the appointment of Mr. D. Muralidharan (DIN: 08301904) as the Whole-Time Director of the Company for a period of two (2) years, with effect from August 12, 2026, to August 11, 2028, subject to the approval of Shareholders at the ensuing AGM. Mr. Muralidharan shall continue as the Chief Financial Officer of the Company in addition to him being designated the Whole Time Director. The details of the above Directors, in accordance with Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as “Annexure- A". Kindly take the same on your records. Sincerely Yours For Caplin Point Laboratories Limited Venkatram G General Counsel & Company Secretary Membership No. A23989 Encl: A/a ANNEXURE – A S.No Particular Dr. Sridhar Ganesan Mr. D. Muralidharan 1 Reason for change viz. Re-appointment of Appointment of Mr. appointment, re- Dr. Sridhar Ganesan D. Muralidharan (DIN: 08301904) as appointment, resignation, (DIN: 06819026) as the the Whole-Time Director of the removal, death or Managing Director of the Company otherwise Company 2 Date of appointment/re- August 25, 2026 August 12, 2026 appointment/cessation (as applicable) & term of appointment/re- appointment; 3 Brief profile Dr. Sridhar Ganesan has over Mr. D. Muralidharan has been serving 35 years of global leadership as the Chief Financial Officer (CFO) of experience in the the Company since February 19, pharmaceutical industry, with 2016. He is a seasoned finance expertise spanning profit professional with rich academic centre management, global credentials, holding a bachelor’s marketing, international degree in commerce (B. Com), business development, project Associate Membership of the planning and implementation, Institute of Company Secretaries of production, new product India (ICSI), and Cost & Management development, quality Accountant qualification from assurance and factory Institute of Cost Accountants of India management. He has held (ICMAI). He is also a member of the leadership positions across Risk Management Committee of the various international Company. assignments, with extensive experience in South Asia, the Middle East and Africa. As Managing Director of the Company, he provides strategic leadership in driving the Company’s growth and expanding its global footprint. 4 Disclosure of relationships NIL Nil between directors (in case of appointment of a director). 5 Information required Dr. Sridhar Ganesan is not Mr. D. Muralidharan is not debarred pursuant to BSE Circular debarred from holding the from holding the office of director by no. office of director by virtue of virtue of any SEBI order or any other LIST/COMP/14/2018-19 any SEBI order or any other such authority. and the such authority. NSE Circular no. NSE/ CML/2018/24, both dated 20th June 2018